Screener
Bristol-Myers Squibb BMY Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on trailing twelve months.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
FAQ
- What is Bristol-Myers Squibb's return on equity?
- Bristol-Myers Squibb (BMY) reported return on equity of 46.7% in Q2 2026.
- How has Bristol-Myers Squibb's return on equity changed year-over-year?
- Bristol-Myers Squibb's return on equity increased by 61.6% year-over-year, from 28.9% to 46.7%.
- What is the long-term trend for Bristol-Myers Squibb's return on equity?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's return on equity has grown at a 15.0% compound annual growth rate (CAGR), from -20.2% to 40.5%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Bristol-Myers Squibb's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude